Latest Security News

ARC Funds Limited’s trading suspension has been lifted following key announcements about new board appointments, signaling a fresh chapter for the investment manager.

Vulcan Energy has obtained its inaugural lithium production licence for the Lionheart Project in Germany, marking a pivotal step as the project moves into funded construction. This licence supports Vulcan’s ambition to supply Europe with sustainable lithium for electric vehicle batteries, backed by renewable energy co-production.

Atlantic Lithium has raised up to US$16.4 million through strategic Ghanaian pension fund investments and a placement with Long State Investments, advancing its flagship Ewoyaa Lithium Project towards production.

Vintage Energy launches a $2.1 million entitlement offer to fund critical oil prospect evaluations and install a permanent connection to the Odin gas field, aiming to cut operating costs and advance drilling plans.

Ark Mines Limited has secured a crucial mining licence for its Sandy Mitchell Rare Earths Project in North Queensland, marking a key step toward development and commercialisation.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Challenger Limited has lowered its non-binding offer for Pepper Money to $2.25 per share, adjusting for upcoming dividends, marking its final bid amid ongoing negotiations.

Native Mineral Resources Holdings Limited has locked in exclusive 12-month mining rights at the Podosky Gold Project in Queensland, backed by promising high-grade drilling results and imminent mining plans.

Almonty Industries has completed Phase 1 commissioning of the Sangdong Tungsten Mine in South Korea, marking its first production in over 30 years and setting the stage for a major expansion.

Clarity Pharmaceuticals has unveiled compelling Phase II trial results showing its Cu-SAR-bisPSMA PET imaging agent significantly improves detection of prostate cancer recurrence over the current standard. The data, presented at the 2026 European Association of Urology Congress and accepted by European Urology journal, mark a key milestone ahead of regulatory submissions.

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.